RE: "Dr. Cruz Quips......Live From New York City"
Winer......NN is concentrating on Liraglutide a proprietary GLP1 Analogue that is administered once daily by injecting and has good results as well with decreasing HBA1C levels. These HBA1C results are quite similar to E1-INT in percentage decrease, when taking into account the higher HBA1C levels enrolled by Novo compared to E1-INT but E1-INT has 6 months sustained effects after a months treatment......not just 24 hours. It is this showing of Increased Beta Cell Function that Transition is persuing.
NN is playing catch-up with Byetta and is targeting obesity more vigorously than them. The GLP1 Analogs all show the ability to reduce weight.......but so does G1.....it has always shown to delay gastric emptying as well and is actually considered the reason that GLP1 has this great side effect in later stage clinical trials . Administration of GLP1 increases the body's secretion of a lot more G1. These factors are the reason that G1 IS GETTING IT'S OWN PHASEll all of a sudden. That and the fact that it's safety profile is absolutely CLEAN!! GLP1 has the nausea to contend with. E1-INT does as well
NN may be happy with a market share of Byettas blockbuster sales .........but Byetta LAR is being developed. It is a once weekly treatment based on a delayed drug release technology they have licensed from another company . Look for them to push the weight loss angle as well.
GLP1-INT could very well be a weekly or monthly treatment......it is considered to be a more chronic treatment than E1-INT based on all data. Plus it really should show a very good weight loss effect if given the chance......LOL.
The reason weight loss is such a great consideration is that the other anti diabetic drugs show a weight gain effect which is counter productive when obesity is so closely linked to Diabetes.
DPP-IV Inhibitors however are weight gain/loss neutral.......BUT with no side effects and are taken Orally.
Short answer.....Yes it does.
But for NN right now they just want to get Liraglutide approved to capture some market share from Byetta. They are however looking at an expanded agreement with Transition ..........but so are some other companys.